Motus GI (MOTS) Stock Price, News & Analysis

Company Overview

Motus GI Holdings, Inc. is a clinical-stage medical technology company developing advanced endoscopic solutions for the minimally invasive diagnosis and treatment of gastrointestinal disorders. The company’s platform is designed to improve procedural control, stability and precision during complex therapeutic interventions in the GI tract, such as tissue resection, hemostasis and suturing. By integrating electromechanical instruments into a single-use device, Motus GI aims to enhance clinical efficiency and patient outcomes compared with conventional flexible endoscopes.

The company’s lead product candidate is an electromechanical endoscopy system built around a multifunctional, disposable module that delivers stable instrument control and intuitive maneuverability. The platform incorporates proprietary motorized elements and disposable accessory channels, enabling physicians to perform a broad spectrum of advanced therapeutic procedures through natural orifice access. Motus GI has secured intellectual property covering instrument actuation, device assembly and system control software, and is conducting pre-commercial and clinical validation studies in the United States.

Headquartered in California, Motus GI serves hospitals, ambulatory surgery centers and endoscopy clinics across North America. Its management team brings extensive experience in medical device development, regulatory affairs and commercialization for minimally invasive surgical technologies. The company continues to advance its clinical and regulatory programs, positioning its platform for future market entry in the United States and select international markets.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0120
• Volume: 790 shs
• Average Volume: 5,102 shs
• Market Capitalization: $1.15 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Motus GI Stock Analysis - MarketRank™

Motus GI scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Motus GI.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Motus GI is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Motus GI is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Motus GI has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.11% of the outstanding shares of Motus GI have been sold short.

Short Interest Ratio / Days to Cover

Motus GI has a short interest ratio ("days to cover") of 30.8, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Motus GI does not currently pay a dividend.

Dividend Growth

Motus GI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the outstanding shares of Motus GI have been sold short.

Short Interest Ratio / Days to Cover

Motus GI has a short interest ratio ("days to cover") of 30.8, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for MOTS on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Motus GI to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Motus GI insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.34% of the stock of Motus GI is held by insiders.

Percentage Held by Institutions

Only 20.06% of the stock of Motus GI is held by institutions.

MOTS Stock Analysis - Frequently Asked Questions

How have MOTS shares performed this year?

Motus GI's stock was trading at $0.0002 at the beginning of the year. Since then, MOTS stock has increased by 0.0% and is now trading at $0.0002.

How were Motus GI's earnings last quarter?

Motus GI Holdings, Inc. (NASDAQ:MOTS) posted its earnings results on Friday, November, 12th. The company reported ($30.00) EPS for the quarter, hitting the consensus estimate of ($30.00). The firm earned $0.14 million during the quarter, compared to the consensus estimate of $0.12 million.

When did Motus GI's stock split?

Motus GI's stock reverse split before market open on Thursday, November 2nd 2023.The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Motus GI IPO?

Motus GI (MOTS) raised $21 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 3,500,000 shares at $5.00-$7.00 per share. Piper Jaffray served as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Motus GI?

Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Motus GI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Motus GI investors own include Inovio Pharmaceuticals (INO), Matinas Biopharma (MTNB), NIO (NIO), Tesla (TSLA), Bionano Genomics (BNGO), Acasti Pharma (ACST) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MOTS
• CIK: 1686850
• Web: www.motusgi.com
• Phone: (954) 541-8000
• Fax: 954-541-8265
• Employees: 30
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $319 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 5,769,000
• Free Float: 5,749,000
• Market Cap: $1.15 thousand
• Optionable: Not Optionable
• Beta: 1.10